Serum Receptor Activator of Nuclear Factor-κ B Ligand, Osteoprotegrin, and Intact Parathyroid Hormone in Hemodialysis and Renal Transplant Patients

被引:6
|
作者
Rashtchizadeh, Nadereh [2 ]
Ghorbanihaghjo, Amir [1 ]
Argani, Hassan [2 ]
Meimand, Saeed Mahmoudi [2 ]
Safa, Javid [2 ]
Vatankhahan, Hamidreza [2 ]
Shahidi, Maryam [2 ]
机构
[1] Tabriz Univ Med Sci, Biotechnol Res Ctr, Tabriz 51664, Iran
[2] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran
关键词
Hemodialysis; Kidney transplanted patients; Osteoprotegrin; Serum receptor activator of nuclear factor-kappa B ligand; VASCULAR CALCIFICATION; BONE-RESORPTION; DISEASE; OSTEOCLASTOGENESIS; ATHEROSCLEROSIS; EXPRESSION; MARKERS; RATS; OPG;
D O I
10.1111/j.1744-9987.2012.01097.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Serum receptor activator of nuclear factor-? B ligand and osteoprotegrin are mediated to vascular calcification in the general population. Our knowledge is very sparse in hemodialysis and renal transplant patients. Receptor activator of nuclear factor-? B ligand, osteoprotegrin, intact parathyroid hormone, calcium, and phosphorus were measured in blood samples of 45 hemodialysis and 45 age-matched renal transplant patients. Osteoprotegrin (P = 0.001) and intact parathyroid hormone (P = 0.001) levels in the hemodialysis patients were higher than the renal transplant recipients. Osteoprotegrin had positive correlation with duration of dialysis and age in the hemodialysis (r = 0.88, P = 0.001 and r = 0.34, P = 0.02, respectively) and renal transplant patients (r = 0.92, P = 0.001 and r = 0.46, P = 0.001, respectively). Hemodialysis patients have higher osteoprotegrin levels than the renal transplant recipients. It may act as a protective factor for renal osteodystrophy or only as a secondary phenomenon of advanced renal failure.
引用
收藏
页码:600 / 604
页数:5
相关论文
共 50 条
  • [1] Receptor Activator of Nuclear Factor-κB Ligand (RANKL) and Its Relationship to Coronary Atherosclerosis in HIV Patients
    Hwang, Janice J.
    Wei, Jeffrey
    Abbara, Suhny
    Grinspoon, Steven K.
    Lo, Janet
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 61 (03) : 359 - 363
  • [2] Differential expression of periostin, sclerostin, receptor activator of nuclear factor-κB, and receptor activator of nuclear factor-κB ligand genes in severe chronic periodontitis
    Sankardas, Pooja A.
    Lavu, Vamsi
    Lakakula, Bhaskar V. K. S.
    Rao, Suresh R.
    JOURNAL OF INVESTIGATIVE AND CLINICAL DENTISTRY, 2019, 10 (01) : e12369
  • [3] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05) : 633 - 642
  • [4] Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media
    Kuczkowski, Jerzy
    Sakowicz-Burkiewicz, Monika
    Izycka-Swieszewska, Ewa
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2010, 31 (06) : 404 - 409
  • [5] Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
    Jiao, Mengyu
    Zhang, Pengmei
    Yu, Xinbo
    Sun, Pei
    Liu, Meiwei
    Qiao, Yanya
    Pan, Keqing
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2022, 24 (02)
  • [6] Changes in serum levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, IL-6 and TNF-α in patients with a concomitant head injury and fracture
    Lee, Jung Sub
    Ryu, Chang Hoon
    Moon, Nam Hoon
    Kim, Seong-Jang
    Park, Shin Young
    Suh, Kuen Tak
    ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY, 2009, 129 (05) : 711 - 718
  • [7] Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro
    Owen, Sioned
    Sanders, Andrew J.
    Mason, Malcolm D.
    Jiang, Wen G.
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 48 (03) : 919 - 928
  • [8] Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease
    Kiechl, Stefan
    Schett, Georg
    Schwaiger, Judith
    Seppi, Klaus
    Eder, Paula
    Egger, Georg
    Santer, Peter
    Mayr, Agnes
    Xu, Qingbo
    Willeit, Johann
    CIRCULATION, 2007, 116 (04) : 385 - 391
  • [9] The Effect of Osteoprotectin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) Gene Methylation on Aortic Valve Calcified
    Luo, Wei
    Song, Yanqiu
    Wang, Jing
    Yang, Xia
    Li, Zuocheng
    Cong, Hongliang
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [10] STUDY OF SERUM OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND IN PATIENTS WITH RHEUMATIC DISEASES
    Geneva-Popova, Mariela
    Popova, Stanislava
    JOURNAL OF IMAB, 2021, 27 (04): : 4170 - 4177